TearClear Appoints Robert Bailey to Board of Directors

UF startup and UF Innovate | Sid Martin Biotech resident client TearClear, a global ophthalmic pharmaceutical company, announces the appointment of industry veteran Robert Bailey to the company’s Board of Directors. Mr. Bailey brings over two decades of leadership experience in the Ophthalmology industry having served on the executive teams as General Counsel/Chief Legal Officer for Allergan and Bausch + Lomb.

“We welcome Bob’s leadership, judgment, and industry expertise to our Board,” said TearClear CEO Robert Dempsey. “His extensive M&A and Public Markets experience will be a tremendous asset as we seek to advance the mission of TearClear.”

Learn more about TearClear Appoints Robert Bailey to Board of Directors.